{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:42:33Z","timestamp":1792672953730,"version":"4.5.0"},"reference-count":50,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Fluoroquinolones (FQs) are broad-spectrum second-line antimicrobial drugs commonly used in the treatment of tuberculosis (TB). Data on FQ resistance in the Khyber Pakhtunkhwa (KP) province of Pakistan, a high-burden country, are scarce. This study aimed to analyze the resistance to FQs in this specific geographic area. Samples were collected from 25 districts of KP from 2014 to 2019. Data regarding suspected TB patients were collected from their guardians or secondary caregivers. All the samples were subjected to decontamination and digestion processing. Drug susceptibility testing (DST) was performed according to the standard minimum inhibitory concentration for ofloxacin (OFX), levofloxacin (LEV), and moxifloxacin (MOX), taken as 2, 1, and 1\u2009\u03bcg\/mL, respectively. For the 5,759 clinical samples collected from 25 districts, DST was conducted for a total of 3,158 samples. Out of the total DSTs, the OFX profile was available for 2,983, MOX profile for 2,290, and LEV profile for 544 samples. OFX and LEV resistance was found to be evenly distributed and has remained the same for the past few years, whereas MOX resistance increased from 1% in 2017 to 4% in 2019. Among a total of 807 OFX-resistant isolates, 218 (27%) were observed to be monoresistant to OFX, whereas 589 (73%) isolates were resistant to OFX and at least one other anti-TB drug. Drug resistance to OFX was higher in multidrug-resistant TB (MDR-TB), that is, 428 (53%). It was concluded that resistance to MOX has been increasing, whereas OFX resistance is much higher in MDR cases. FQ resistance needs to be continuously monitored to avoid further side effects. This study provides useful information for better management of FQ resistance with reference to the global TB control program 2030.<\/jats:p>","DOI":"10.1089\/mdr.2020.0118","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T11:25:03Z","timestamp":1604057103000},"page":"786-791","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluoroquinolone Resistance Among Isolates of\n                    <i>Mycobacterium tuberculosis<\/i>\n                    in Khyber Pakhtunkhwa, Pakistan"],"prefix":"10.1177","volume":"27","author":[{"given":"Sajid","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Microbiology, Quaid-i-Azam University Islamabad, Islamabad, Pakistan."},{"name":"Provincial TB Reference Laboratory, Khyber Pakhtunkhwa, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Tahir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Bioscience, Capital University of Science and Technology, Islamabad, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar Sheed","family":"Khan","sequence":"additional","affiliation":[{"name":"Kohat University of Science and Technology and Provincial TB Reference Laboratory, Khyber Pakhtunkhwa, Kohat, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim","family":"Abbas","sequence":"additional","affiliation":[{"name":"TB Control Programme, Khyber Pakhtunkhwa, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Irfan","sequence":"additional","affiliation":[{"name":"Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"471","article-title":"Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis","volume":"114","author":"African, S.E","year":"2015","unstructured":"African, S.E. 2015. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 114:471\u2013475.","journal-title":"Am. Rev. Respir. Dis"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.diagmicrobio.2015.10.017","article-title":"Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations","volume":"84","author":"Gu Y.","year":"2016","unstructured":"Gu Y., , Yu X., , Jiang G., , Wang X., , Ma Y., , Li Y., , and Huang H.. 2016. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn. Microbiol. Infect. Dis. 84:207\u2013211.","journal-title":"Diagn. Microbiol. Infect. Dis"},{"key":"e_1_3_3_4_2","first-page":"705","article-title":"Pyrazinamide-resistant Mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa and rpsA mutations","volume":"32","author":"Khan M.T.","year":"2018","unstructured":"Khan M.T., , Malik S.I, , Bhatti A.I, , Ali S., , Khan A.S, , Zeb M.T, , Nadeem T., , and Fazal S.. 2018. Pyrazinamide-resistant Mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa and rpsA mutations. J. Biol. Regul. Homeost. Agents, 32:705\u2013709.","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1128\/AAC.00287-09","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB","volume":"53","author":"Groll A.V.","year":"2009","unstructured":"Groll A.V., , Martin A., , Jureen P., , Hoffner S., , Vandamme P., , Portaels F., , Palomino J.C, , and da Silva P.A.. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498\u20134500.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_6_2","first-page":"P2617","article-title":"Prevalence of fluoroquinolone resistance in Mycobacterium tuberculosis in a tertiary care hospital in India","volume":"44","author":"Kale M.","year":"2014","unstructured":"Kale M., , Khatavkar P., , Satpute M., , and Telang N.. 2014. Prevalence of fluoroquinolone resistance in Mycobacterium tuberculosis in a tertiary care hospital in India. Eur. Respir. J. 44:P2617.","journal-title":"Eur. Respir. J"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang Z.","year":"2014","unstructured":"Zhang Z., , Lu J., , Wang Y., , Pang Y., , and Zhao Y.. 2014. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob. Agents Chemother. 58:364\u2013369.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0234"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.01.026"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/md17100549","article-title":"Marine natural products and drug resistance in latent tuberculosis","volume":"17","author":"Khan M.T.","year":"2019","unstructured":"Khan M.T., , Kaushik A.C, , Bhatti A.I, , Zhang Y.-J, , Zhang S., , Wei A.J, , Malik S.I, , and Wei D.Q.. 2019. Marine natural products and drug resistance in latent tuberculosis. Mar. Drugs, 17:549.","journal-title":"Mar. Drugs"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fcimb.2017.00151","article-title":"Genomic insight into mechanisms of reversion of antibiotic resistance in multidrug resistant Mycobacterium tuberculosis induced by a nanomolecular iodine-containing complex FS-1","volume":"7","author":"Ilin A.I.","year":"2017","unstructured":"Ilin A.I., , Kulmanov M.E, , Korotetskiy I.S, , Islamov R.A, , Akhmetova G.K, , Lankina M.V, , and Reva O.N.. 2017. Genomic insight into mechanisms of reversion of antibiotic resistance in multidrug resistant Mycobacterium tuberculosis induced by a nanomolecular iodine-containing complex FS-1. Front. Cell. Infect. Microbiol. 7:151.","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.arabjc.2011.04.008","article-title":"Synthesis and antibacterial evaluation of novel analogs of fluoroquinolones annulated with 6-substituted-2-aminobenzothiazoles","volume":"8","author":"Sharma P.C.","year":"2015","unstructured":"Sharma P.C., , Jain A., , Yar M.S, , Pahwa R., , Singh J., , and Goel S.. 2015. Synthesis and antibacterial evaluation of novel analogs of fluoroquinolones annulated with 6-substituted-2-aminobenzothiazoles. Arab. J. Chem. 8:671\u2013677.","journal-title":"Arab. J. Chem"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00706-018-2215-x","article-title":"Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules","volume":"149","author":"Fedorowicz J.","year":"2018","unstructured":"Fedorowicz J., , and S\u0105czewski J.. 2018. Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules. Monatshefte Chem. 149:1199\u20131245.","journal-title":"Monatshefte Chem"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fmicb.2017.00578","article-title":"Mutation at G103 of MtbFtsZ altered their sensitivity to coumarins","volume":"8","author":"Sridevi D.","year":"2017","unstructured":"Sridevi D., , Sudhakar K.U, , Ananthathatmula R., , Nankar R.P, , and Doble M.. 2017. Mutation at G103 of MtbFtsZ altered their sensitivity to coumarins. Front. Microbiol. 8:578.","journal-title":"Front. Microbiol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00671-6"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1473-3099(13)70130-0","article-title":"Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data","volume":"13","author":"Falzon D.","year":"2013","unstructured":"Falzon D., , Jaramillo E., , Wares F., , Zignol M., , Floyd K., , and Raviglione M.C.. 2013. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect. Dis. 13:690\u2013697.","journal-title":"Lancet Infect. Dis"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/AAC.00177-09","article-title":"Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China","volume":"53","author":"Xu P.","year":"2009","unstructured":"Xu P., , Li X., , Zhao M., , Gui X., , DeRiemer K., , Gagneux S., , Mei J., , and Gao Q.. 2009. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob. Agents Chemother. 53:3170\u20133172.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00695-11"},{"key":"e_1_3_3_19_2","first-page":"Ethiopia","article-title":"Performance evaluation of MDR-TB color plate Test for rapid detection of Mycobacterium tuberculosis and multidrug-resistant tuberculosis in resource limited setting","author":"Abebe T.","year":"2017","unstructured":"Abebe T. 2017. Performance evaluation of MDR-TB color plate Test for rapid detection of Mycobacterium tuberculosis and multidrug-resistant tuberculosis in resource limited setting. Addis Ababa University, Addis, Ababa, Ethiopia.","journal-title":"Addis Ababa University, Addis"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/AAC.04058-14","article-title":"Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis","volume":"59","author":"Bernard C.","year":"2015","unstructured":"Bernard C., , Veziris N., , Brossier F., , Sougakoff W., , Jarlier V., , Robert J., , and Aubry A.. 2015. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59:1519\u20131524.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1128\/AAC.01749-15","article-title":"Impact of fluoroquinolone exposure prior to tuberculosis diagnosis on clinical outcomes in immunocompromised patients","volume":"60","author":"Lee J.Y.","year":"2016","unstructured":"Lee J.Y., , Lee H.J, , Kim Y.K, , Yu S., , Jung J., , Chong Y.P, , Lee S.-O, , Choi S.-H, , Shim T.S, , Kim Y.S, , Woo J.H, , and Kim S.-H.. 2016. Impact of fluoroquinolone exposure prior to tuberculosis diagnosis on clinical outcomes in immunocompromised patients. Antimicrob. Agents Chemother. 60:4005\u20134012.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.968"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","unstructured":"Ali S. Khan M.T Khan A.S Mohammad N. Khan M.M Ahmad S. Noor S. Jabbar A. Daire C. and Hassan F.. 2020. Prevalence of multi-drug resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa\u2014a high tuberculosis endemic area of Pakistan. 69:1\u20135.","DOI":"10.33073\/pjm-2020-005"},{"key":"e_1_3_3_24_2","first-page":"1","article-title":"Prevalence of multi-drug resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa\u2014a high tuberculosis endemic area of Pakistan","volume":"69","author":"Ali S.","year":"2020","unstructured":"Ali S., , Khan M.T, , Khan A.S, , Mohammad N., , Khan M.M, , Ahmad S., , Noor S., , Jabbar A., , Daire C., , and Hassan F.. 2020. Prevalence of multi-drug resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa\u2014a high tuberculosis endemic area of Pakistan. Pol. J. Microbiol. 69:1\u20135.","journal-title":"Pol. J. Microbiol"},{"key":"e_1_3_3_25_2","first-page":"775","article-title":"Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria","volume":"87","author":"Kubica G.P.","year":"1963","unstructured":"Kubica G.P., , Dye W.E, , Cohn M.L, , and Middlebrook G.. 1963. Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. Am. Rev. Respir. Dis. 87:775\u2013779.","journal-title":"Am. Rev. Respir. Dis"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"e00038","DOI":"10.1128\/CMR.00038-17","article-title":"Practice guidelines for clinical microbiology laboratories: mycobacteria","volume":"31","author":"Forbes B.A.","year":"2018","unstructured":"Forbes B.A., , Hall G.S, , Miller M.B, , Novak S.M, , Rowlinson M.-C, , Salfinger M., , Somosk\u00f6vi A., , Warshauer D.M, , and Wilson M.L.. 2018. Practice guidelines for clinical microbiology laboratories: mycobacteria. Clin. Microbiol. Rev. 31:e00038\u201317.","journal-title":"Clin. Microbiol. Rev"},{"key":"e_1_3_3_27_2","unstructured":"WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization Geneva."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/acscombsci.5b00019"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.10"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12539-016-0175-6","article-title":"Identification of potential antituberculosis drugs through docking and virtual screening","volume":"10","author":"Anand R.","year":"2018","unstructured":"Anand R. 2018. Identification of potential antituberculosis drugs through docking and virtual screening. Interdiscip. Sci. Comput. Life Sci. 10:419\u2013429.","journal-title":"Interdiscip. Sci. Comput. Life Sci"},{"key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12539-017-0257-0","article-title":"In silico drug design of thiolactomycin derivatives against Mtb-KasA enzyme to inhibit multidrug resistance of Mycobacterium tuberculosis","volume":"11","author":"Durairaj D.R.","year":"2019","unstructured":"Durairaj D.R., , and Shanmughavel P.. 2019. In silico drug design of thiolactomycin derivatives against Mtb-KasA enzyme to inhibit multidrug resistance of Mycobacterium tuberculosis. Interdiscip. Sci. Comput. Life Sci. 11:215\u2013225.","journal-title":"Interdiscip. Sci. Comput. Life Sci"},{"key":"e_1_3_3_32_2","first-page":"58","article-title":"Characterization of the W321F mutant of Mycobacterium tuberculosis catalase\u2013peroxidase KatG","volume":"11","author":"Yu S.","year":"2002","unstructured":"Yu S., , Chouchane S., , and Magliozzo R.S.. 2002. Characterization of the W321F mutant of Mycobacterium tuberculosis catalase\u2013peroxidase KatG. Protein Sci. 11:58\u201364.","journal-title":"Protein Sci"},{"key":"e_1_3_3_33_2","first-page":"79","article-title":"Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India","volume":"13","author":"Agrawal D.","year":"2009","unstructured":"Agrawal D., , Udwadia Z.F, , Rodriguez C., , and Mehta A.. 2009. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 13:79\u201383.","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8023935"},{"key":"e_1_3_3_35_2","first-page":"679","volume":"36","author":"Bidell M.R.","year":"2016","unstructured":"Bidell M.R., , and Lodise T.P.. 2016. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy, 36:679\u2013693.","journal-title":"Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1178-1182.2006"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/340618"},{"key":"e_1_3_3_38_2","first-page":"1215","article-title":"Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia","volume":"9","author":"Yoon Y.S.","year":"2005","unstructured":"Yoon Y.S., , Lee H.J, , Yoon H.I, , Yoo C.-G, , Kim Y.W, , Han S.K, , Shim Y.-S, , and Yim J.-J.. 2005. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int. J. Tuberc. Lung Dis. 9:1215\u20131219.","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"e_1_3_3_39_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1183\/09031936.00070407","article-title":"Quinolones to treat acute bacterial exacerbation of chronic bronchitis in TB endemic areas: a word of caution","volume":"30","author":"Singh A.","year":"2007","unstructured":"Singh A. 2007. Quinolones to treat acute bacterial exacerbation of chronic bronchitis in TB endemic areas: a word of caution. Eur. Respir. J. 30:1233.","journal-title":"Eur. Respir. J"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200311133492023"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01400-08"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0140-6736(95)90980-X","article-title":"Emergence of fluoroquinolone-resistant tuberculosis in New York City","volume":"345","author":"Sullivan E.A.","year":"1995","unstructured":"Sullivan E.A., , Palumbo L., , Ebrahimzadeh A., , Frieden T.R, , Kreiswirth B.N, , Kapur V., , and Musser J.M.. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet, 345:1148\u20131150.","journal-title":"Lancet"},{"key":"e_1_3_3_43_2","doi-asserted-by":"crossref","unstructured":"Huang T.-S. Kunin C.M Shin-Jung Lee S. Chen Y.-S Tu H.-Z and Liu Y.-C. 2005. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J. Antimicrob. Chemother. 56:1058\u20131062.","DOI":"10.1093\/jac\/dki353"},{"key":"e_1_3_3_44_2","first-page":"546","article-title":"Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines","volume":"5","author":"Grimaldo E.R.","year":"2001","unstructured":"Grimaldo E.R., , Tupasi T.E, , Rivera A.B, , Quelapio M.I, , Carda\u00f1o R.C, , Derilo J.O, , and Belen V.A.. 2001. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5:546\u2013550.","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"e_1_3_3_45_2","first-page":"136","article-title":"Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China","volume":"16","author":"Chen J.","year":"2012","unstructured":"Chen J., , Chen Z., , Li Y., , Xia W., , Chen X., , Chen T., , Zhou L., , Xu B., , and Xu S.. 2012. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz. J. Infect. Dis. 16:136\u2013141.","journal-title":"Braz. J. Infect. Dis"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","article-title":"Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin","volume":"62","author":"Nosova E.Y.","year":"2013","unstructured":"Nosova E.Y., , Bukatina A.A, , Isaeva Y.D, , Makarova M.V, , Galkina K.Y, , and Moroz A.M.. 2013. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J. Med. Microbiol. 62:108\u2013113.","journal-title":"J. Med. Microbiol"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijantimicag.2012.01.007","article-title":"Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance","volume":"39","author":"Suzuki Y.","year":"2012","unstructured":"Suzuki Y., , Nakajima C., , Tamaru A., , Kim H., , Matsuba T., , and Saito H.. 2012. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. Int. J. Antimicrob. Agents, 39:435\u2013439.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1128\/AAC.00042-11","article-title":"Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance","volume":"55","author":"Kim H.","year":"2011","unstructured":"Kim H., , Nakajima C., , Yokoyama K., , Rahim Z., , Kim Y.U, , Oguri H., , and Suzuki Y.. 2011. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob. Agents Chemother. 55:3661\u20133667.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_49_2","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1128\/AAC.00506-13","article-title":"Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis","volume":"57","author":"Fillion A.","year":"2013","unstructured":"Fillion A., , Aubry A., , Brossier F., , Chauffour A., , Jarlier V., , and Veziris N.. 2013. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob. Agents Chemother. 57:4496\u20134500.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_50_2","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1128\/AAC.00968-10","article-title":"Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model","volume":"54","author":"Poissy J.","year":"2010","unstructured":"Poissy J., , Aubry A., , Fernandez C., , Lott M.-C, , Chauffour A., , Jarlier V., , Farinotti R., , and Veziris N.. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 54:4765\u20134771.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_3_51_2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u201c9-month Bangladesh regimen\u201d for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung K.J.M.","year":"2014","unstructured":"Aung K.J.M., , Van Deun A., , Declercq E., , Sarker M.R, , Das P.K, , Hossain M.A, , and Rieder H.L.. 2014. Successful \u201c9-month Bangladesh regimen\u201d for multidrug-resistant tuberculosis among over 500 consecutive patients. Int. J. Tuberc. Lung Dis. 18:1180\u20131187.","journal-title":"Int. J. Tuberc. Lung Dis"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2020.0118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:37:43Z","timestamp":1777667863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2020.0118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1089\/mdr.2020.0118"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2020.0118","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}